Stock fact sheet · data as of
Rallybio Corporation (RLYB): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · Value
Is RLYB undervalued?
Rallybio Corporation (RLYB) closed at 16.91 on 16 Oct 2026. The GLS average fair value - the simple average of the 8 valuation models that produced a positive number - is 120.56, which puts the price 86% below it. 6 of the 8 models value the shares above the current price. A gap this wide is rare in our universe of ~7,400 US stocks and is exactly what the Value part of the Wheel Score rewards; it is also where the question "why is it this cheap?" matters most.
There is a wide gap between GLS Growth (4.37) and Graham Growth (440.94). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
The nightly engine files RLYB under Value: positive earnings at a P/E of 18 or less.
Nine valuation models for RLYB
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 9.83 | -42% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | 54.61 | +223% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 440.94 | +2508% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 191.51 | +1033% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 4.37 | -74% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 97.08 | +474% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 77.36 | +358% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 88.81 | +425% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 10.72 | -37% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Rallybio Corporation scores 5 of 9 on the Piotroski F-score: a middling result that falls one point short of the Sunday Scan's "6 or more" rule. Some of the nine tests on profitability, leverage and efficiency are failed, so the accounts are worth a look before selling a put on the name. A GLS Moat score of 2.0/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC -15.4%, ROE -15.5%, ROA -14.4% - with debt at 0.00 times equity and a free-cash-flow yield of 29.3%.
Rallybio Corporation pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Collaboration And License Revenue 100% (quarter Q1 FY2026).
Institutional ownership scores 10/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales; the last recorded insider buy was on 16 Sep 2026.
| Piotroski F-score | 5 / 9 | ROIC | -15.4% |
|---|---|---|---|
| GLS Moat | 2.0 / 10 | ROE | -15.5% |
| Debt / equity | 0.00 | ROA | -14.4% |
| Free-cash-flow yield | 29.3% | Payout ratio | 0% |
| Institutions | 10 / 10 | Insiders · Congress | 10 · 5 / 10 |
Wheel Score 39: No options
No options are listed on Rallybio Corporation in our nightly snapshot. The Wheel Score is therefore capped at 39 (it reads 39) and the stock is left out of every options screen; the fair value and health figures above are still useful for a plain stock position.
Volume runs at 5k shares a day on a market cap of $90M, with a beta of -0.85 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 6 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 86% margin of safety | |
| Health | 11 / 20 | Piotroski 5/9 | |
| Moat | 3 / 15 | moat 2.0/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 6 / 20 | 5k shares/day, $90M cap, beta -0.85 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 5 Nov 2026, 20 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Rallybio Corporation by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| ADAG Adagene Inc. | 2.40 | - | - | 36No options | $90M |
| TNYA Tenaya Therapeutics, Inc. | 0.3905 | 0.5664 | +31% | 45Weak | $88M |
| OKUR OnKure Therapeutics, Inc. | 2.13 | 4.23 | +50% | 45Weak | $86M |
| AARD Aardvark Therapeutics, Inc. Common Stock | 3.86 | 2.06 | -87% | 10Weak | $84M |
| ICCC ImmuCell Corporation | 10.56 | 4.35 | -143% | 26No options | $96M |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | 4.33 | 1.97 | -120% | 24Weak | $84M |
| EQ Equillium, Inc. | 1.32 | 0.3155 | -318% | 15Weak | $84M |
| ANIX Anixa Biosciences, Inc. | 2.78 | 0.0273 | -10072% | 19Weak | $97M |
| ATRA Atara Biotherapeutics, Inc. | 9.65 | - | - | 25No options | $97M |
| IMUX Immunic, Inc. | 7.10 | 0.6047 | -1074% | 18Weak | $97M |
| NRXS NeurAxis, Inc. | 7.74 | - | - | 45Weak | $97M |
| PYPD PolyPid Ltd. | 4.83 | 0.1249 | -3766% | 18Weak | $98M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about RLYB
Is RLYB undervalued right now?
By the GLS models, yes: at 16.91 the stock is 86% below the average fair value of 120.56 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of RLYB and what does it mean?
RLYB has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for RLYB?
120.56 per share as of 16 Oct 2026 - the simple average of the 8 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Rallybio Corporation report earnings next?
The next earnings report is due on 5 Nov 2026, 20 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does RLYB have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on RLYB, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.